Mucopolysaccharidosis type II arises from deficient or absent activity of iduronate 2-sulfatase, an enzyme encoded by the IDS gene on the X chromosome. This enzyme is required for stepwise lysosomal degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. Without functional enzyme activity, these substrates accumulate progressively within lysosomes across multiple organ systems, disrupting cellular function and producing the multisystem features of the condition. The X-linked inheritance pattern means the condition predominantly affects males, who carry a single X chromosome and have no compensatory copy of the gene. Female carriers, with a second X chromosome, are typically unaffected or more mildly affected, though variable X-chromosome inactivation can lead to clinical findings in some heterozygous females. The phenotypic severity of MPS II correlates in part with the nature and functional impact of the pathogenic IDS variant present.

Per clinical review, the diagnosis of mucopolysaccharidosis type II cannot be established on clinical findings alone, as manifestations vary widely and evolve over time. Biochemical assessment demonstrating deficient iduronate 2-sulfatase enzyme activity, combined with molecular genetic testing identifying a pathogenic variant in the IDS gene, provides diagnostic confirmation. Urinary glycosaminoglycan excretion, universally elevated in affected individuals, is an additional biochemical indicator used in the evaluation. Newborn screening programs that include MPS II employ enzyme activity quantification on dried bloodspot specimens to enable early identification before symptom onset. Skeletal radiographic assessment for dysostosis multiplex and neuroimaging contribute to characterization of disease extent and phenotypic form. The differential diagnosis encompasses other mucopolysaccharidoses and lysosomal storage disorders with overlapping clinical features. Per clinical review, the trajectory of clinical and radiographic findings over time is an important indicator in the overall diagnostic picture.

Intravenous idursulfase (Elaprase), a recombinant form of human iduronate 2-sulfatase, received FDA approval in 2006 as enzyme replacement therapy (ERT) for mucopolysaccharidosis type II. ERT is administered on an ongoing basis and reduces glycosaminoglycan accumulation in peripheral tissues by supplying the deficient enzyme. Per clinical review, idursulfase does not cross the blood-brain barrier in sufficient quantities to address central nervous system involvement in the neuronopathic form of the condition. Supportive and multidisciplinary care addresses airway management, cardiac evaluation and management, orthopedic and musculoskeletal needs, and neurodevelopmental support across both phenotypic forms. Several additional agents hold orphan drug designations for MPS II—including IDS-expressing gene therapy vectors and enzyme constructs designed for CNS delivery—but these designations do not confer FDA approval, and these agents are not currently authorized for routine clinical use.

Prognosis in mucopolysaccharidosis type II differs markedly between the two recognized phenotypic forms. Per clinical review, individuals with the neuronopathic form experience progressive cognitive deterioration together with progressive airway and cardiac disease, with death typically occurring during the first or second decade of life. Individuals with the non-neuronopathic form have minimal to no central nervous system involvement, a slower rate of systemic progression, and longer life expectancy, though cardiorespiratory and musculoskeletal complications continue to accumulate over time. Enzyme replacement therapy with idursulfase has contributed to improved management of peripheral tissue glycosaminoglycan burden; longer-term outcomes with ERT and with investigational CNS-directed therapies continue to be assessed in ongoing clinical research. The specific nature of the IDS pathogenic variant and residual enzyme activity are among the factors contributing to the range of individual outcomes.

Mucopolysaccharidosis type II is the subject of an active clinical research landscape encompassing enzyme replacement innovation, gene therapy, and newborn screening. Several registered studies at Phase 1 and Phase 3 levels are currently active or recruiting, including investigations employing AAV-based IDS gene delivery approaches, hematopoietic stem cell-based gene therapy, and CNS-penetrant enzyme delivery formats. Efforts to address central nervous system involvement—the primary limitation of existing ERT—represent a central focus of the research agenda, with multiple CNS-directed approaches in clinical evaluation. Published research documentation in this area encompasses over 100 classified publications including case reports, case series, review articles, and original clinical investigations, with gene therapy and biomarker publication activity documented. Expanded newborn screening initiatives include MPS II among conditions under prospective evaluation in multi-disease screening registries.